

# Abdullatif Al-Khal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8970528/publications.pdf>

Version: 2024-02-01

71  
papers

5,139  
citations

159358

30  
h-index

128067

60  
g-index

89  
all docs

89  
docs citations

89  
times ranked

4629  
citing authors

#	ARTICLE	IF	CITATIONS
1	Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e1188-e1191.	2.9	38
2	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. <i>Nature Communications</i> , 2022, 13, 532.	5.8	53
3	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0262897.	1.1	1
4	Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. <i>New England Journal of Medicine</i> , 2022, 386, 1288-1290.	13.9	356
5	Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. <i>JAMA Internal Medicine</i> , 2022, 182, 197.	2.6	81
6	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience. <i>Journal of Global Health</i> , 2022, 12, 05004.	1.2	7
7	Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. <i>Nature Communications</i> , 2022, 13, 946.	5.8	30
8	Clinical and Epidemiological Characteristics of <i>Stenotrophomonas maltophilia</i> Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study. <i>Cureus</i> , 2022, 14, e23263.	0.2	0
9	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 1804-1816.	13.9	311
10	First characterisation of antimicrobial susceptibility and resistance of <i>Neisseria gonorrhoeae</i> isolates in Qatar, 2017-2020. <i>PLoS ONE</i> , 2022, 17, e0264737.	1.1	5
11	Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e361-e367.	2.9	83
12	Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study. <i>PLoS ONE</i> , 2022, 17, e0267884.	1.1	7
13	Reporting of RT-PCR cycle threshold (Ct) values during the first wave of COVID-19 in Qatar improved result interpretation in clinical and public health settings. <i>Journal of Medical Microbiology</i> , 2022, 71, .	0.7	7
14	Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	37
15	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022, 13, .	5.8	188
16	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. <i>New England Journal of Medicine</i> , 2022, 387, 21-34.	13.9	368
17	Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. <i>Clinical Infectious Diseases</i> , 2021, 73, e1830-e1840.	2.9	154
18	Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies. <i>International Journal of Infectious Diseases</i> , 2021, 102, 181-187.	1.5	19

#	ARTICLE	IF	CITATIONS
19	Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report. <i>Journal of Medical Virology</i> , 2021, 93, 1678-1686.	2.5	37
20	Middle East respiratory syndrome coronavirus infection profile in Qatar: An 8-year experience. <i>IDCases</i> , 2021, 24, e01161.	0.4	5
21	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. <i>Journal of Global Health</i> , 2021, 11, 05005.	1.2	71
22	Molecular characteristics of <i>Neisseria meningitidis</i> in Qatar. <i>Scientific Reports</i> , 2021, 11, 4812.	1.6	2
23	COVID-19 vaccine hesitancy and attitudes in Qatar: A national cross-sectional survey of a migrant-majority population. <i>Influenza and Other Respiratory Viruses</i> , 2021, 15, 361-370.	1.5	119
24	Molecular characterization of clinical carbapenem-resistant Enterobacterales from Qatar. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1779-1785.	1.3	22
25	Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. <i>Infection, Genetics and Evolution</i> , 2021, 88, 104684.	1.0	22
26	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. <i>Scientific Reports</i> , 2021, 11, 6233.	1.6	117
27	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. <i>BMJ Innovations</i> , 2021, 7, 327-336.	1.0	27
28	SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab221.	0.4	58
29	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. <i>Emerging Infectious Diseases</i> , 2021, 27, 1343-1352.	2.0	74
30	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	69
31	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. <i>EClinicalMedicine</i> , 2021, 35, 100861.	3.2	153
32	SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. <i>IScience</i> , 2021, 24, 102646.	1.9	79
33	Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. <i>Scientific Reports</i> , 2021, 11, 11837.	1.6	14
34	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <i>Nature Medicine</i> , 2021, 27, 1614-1621.	15.2	337
35	Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 185.	3.8	37
36	Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar. <i>International Journal of Infectious Diseases</i> , 2021, 112, 52-54.	1.5	59

#	ARTICLE	IF	CITATIONS
37	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. <i>Scientific Reports</i> , 2021, 11, 18182.	1.6	49
38	Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. <i>International Journal of Infectious Diseases</i> , 2021, 110, 353-358.	1.5	74
39	SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	49
40	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2021, 385, e83.	13.9	675
41	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1930.	3.8	140
42	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021, 27, 2136-2143.	15.2	346
43	One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 768883.	1.8	56
44	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003879.	3.9	54
45	508. Title Favipiravir for the Treatment of Coronavirus Disease 2019; A Propensity Score Matched Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, S356-S356.	0.4	0
46	1247. Molecular Epidemiology of Multi-drug Resistant <i>Klebsiella pneumoniae</i> and <i>K. quasipneumoniae</i> in Qatar. <i>Open Forum Infectious Diseases</i> , 2021, 8, S712-S712.	0.4	0
47	Job satisfaction and stress among healthcare workers in public hospitals in Qatar. <i>Archives of Environmental and Occupational Health</i> , 2020, 75, 10-17.	0.7	22
48	The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study. <i>BMC Infectious Diseases</i> , 2020, 20, 777.	1.3	41
49	Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 Februaryâ€“18 April 2020. <i>BMJ Open</i> , 2020, 10, e040428.	0.8	82
50	Within-Host Diversity of SARS-CoV-2 in COVID-19 Patients With Variable Disease Severities. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 575613.	1.8	67
51	Molecular epidemiology of influenza, RSV, and other respiratory infections among children in Qatar: A six years report (2012â€“2017). <i>International Journal of Infectious Diseases</i> , 2020, 95, 133-141.	1.5	19
52	Drug-resistant tuberculosis: an experience from Qatar. <i>Libyan Journal of Medicine</i> , 2020, 15, 1744351.	0.8	4
53	Qatar's response to COVID-19 pandemic. <i>Heart Views</i> , 2020, 21, 129.	0.1	14
54	Early laboratory markers may reflect the severity of pyogenic liver abscess infection: Retrospective cohort study. <i>Access Microbiology</i> , 2020, 2, .	0.2	0

#	ARTICLE	IF	CITATIONS
55	Clinical characteristics, microbiology, and outcomes of infective endocarditis in Qatar. Qatar Medical Journal, 2020, 2020, 24.	0.2	6
56	Cerebral schistosomiasis: Case series from Qatar. International Journal of Infectious Diseases, 2019, 86, 167-170.	1.5	11
57	Epidemiology of respiratory infections among adults in Qatar (2012-2017). PLoS ONE, 2019, 14, e0218097.	1.1	19
58	630. Clinical and Molecular Characteristics of Carbapenem-Resistant Enterobacteriaceae in Qatar: A Retrospective and Prospective Observational Study. Open Forum Infectious Diseases, 2019, 6, S292-S292.	0.4	0
59	163. Infective Endocarditis in Qatar: Risk Factors, Clinical Characteristics, Microbiology, and Outcomes. Open Forum Infectious Diseases, 2019, 6, S106-S107.	0.4	0
60	739. Middle East Respiratory Syndrome Coronavirus Infection Profile in Qatar: A 7-Year Retrospective Study. Open Forum Infectious Diseases, 2018, 5, S265-S265.	0.4	0
61	Epidemiology and clinical outcomes of viral central nervous system infections. International Journal of Infectious Diseases, 2018, 73, 85-90.	1.5	33
62	Viral infections of the central nervous system in Qatar: epidemiology, pathogenesis and clinical outcomes. Journal of Infection in Developing Countries, 2018, 12, 29S.	0.5	0
63	Antibiotic prescription patterns for upper respiratory tract infections in the outpatient Qatari population in the private sector. International Journal of Infectious Diseases, 2017, 55, 20-23.	1.5	39
64	Viral Infections of the Central Nervous System in Qatar: Epidemiology, Pathogenesis and Clinical Outcomes. Open Forum Infectious Diseases, 2017, 4, S305-S305.	0.4	0
65	Implementing and tailoring a western-developed communication skills training program for graduate medical trainees in Qatar. International Journal of Medical Education, 2017, 8, 16-18.	0.6	11
66	Burnout and sources of stress among medical residents at Hamad Medical Corporation, Qatar. Eastern Mediterranean Health Journal, 2017, 23, 40-46.	0.3	10
67	Satisfaction with a 2-day communication skills course culturally tailored for medical specialists in Qatar. Journal of Family and Community Medicine, 2017, 24, 122-127.	0.5	2
68	Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar. Clinical Therapeutics, 2016, 38, 1158-1173.	1.1	11
69	Clinician-educators in emerging graduate medical education systems: description, roles and perceptions. Postgraduate Medical Journal, 2016, 92, 14-20.	0.9	14
70	Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference. Clinical Therapeutics, 2015, 37, 2798-2810.	1.1	6
71	COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar. Journal of Global Health, 0, 12, .	1.2	48